Shenzhen Magicrna Biotechnology Co., Ltd

This early study tests a new treatment called HN2302 in 12 adults with lupus or scleroderma. The goal is to see if it is safe and how well it works. The treatment is a type of cell therapy that may help control the immune system.

This early study tests a new treatment called HN2301 in 6 adults with generalized myasthenia gravis, a condition causing muscle weakness. The main goal is to check safety and side effects. Researchers will also measure how the therapy affects immune cells in the blood.